| http://dbpedia.org/ontology/abstract
|
Abarelix (Handelsname: Plenaxis®) ist ein Arzneistoff aus der Gruppe der GnRH-Antagonisten, der zur Behandlung des fortgeschrittenen oder metastasierten hormonabhängigen Prostatakarzinoms eingesetzt wird.
, Abarelix, venut amb la marca Plenaxis, és … Abarelix, venut amb la marca Plenaxis, és un antagonista injectable de l'hormona alliberadora de gonadotropines (antagonista de la GnRH) que es comercialitza a Alemanya i els Països Baixos. S'utilitza principalment en oncologia per reduir la quantitat de testosterona produïda en pacients amb càncer de pròstata simptomàtic avançat per al qual no hi ha altres opcions de tractament disponibles. Va ser comercialitzat originalment per Praecis Pharmaceuticals com a Plenaxis, i ara és comercialitzat per Specialty European Pharma a Alemanya després de rebre una autorització de comercialització el 2005. El medicament es va introduir als Estats Units el 2003, però es va interrompre en aquest al maig del 2005 a causa de les males vendes i d’una incidència més gran de l'esperada de reaccions al·lèrgiques greus. Tanmateix, es manté comercialitzat a Alemanya i els Països Baixos.rcialitzat a Alemanya i els Països Baixos.
, Abarelix é um fármaco antagonista da GnRH. É utilizado principalmente na oncologia para reduzir a quantidade de testosterona dos pacientes com câncer de próstata avançado que não obtiveram sucesso com outros tratamentos.
, Abarelix, sold under the brand name Plenax … Abarelix, sold under the brand name Plenaxis, is an injectable gonadotropin-releasing hormone antagonist (GnRH antagonist) which is marketed in Germany and the Netherlands. It is primarily used in oncology to reduce the amount of testosterone made in patients with advanced symptomatic prostate cancer for which no other treatment options are available. It was originally marketed by Praecis Pharmaceuticals as Plenaxis, and is now marketed by Speciality European Pharma in Germany after receiving a marketing authorization in 2005. The drug was introduced in the United States in 2003, but was discontinued in this country in May 2005 due to poor sales and a higher-than-expected incidence of severe allergic reactions. It remains marketed in Germany and the Netherlands however.ed in Germany and the Netherlands however.
, L'abarelix è un antagonista dell'ormone di … L'abarelix è un antagonista dell'ormone di rilascio delle gonadotropine, l'ormone di rilascio delle gonadotropine. È utilizzato principalmente in oncologia per ridurre la quantità di testosterone in pazienti con tumore avanzato della prostata sintomatico per i quali non sono disponibili altre opzioni di trattamento. È commercializzato da Speciality European Pharma come Plenaxis. Plenaxis ha ricevuto l'autorizzazione all'immissione in commercio in Germania.e all'immissione in commercio in Germania.
, أباريليكس (بالإنجليزية: Abarelix) كما يدع … أباريليكس (بالإنجليزية: Abarelix) كما يدعى plenaxis. دواء يستخدم لخفض كمية التيستوستيرون المنتج في أجسام المرضى الذين يعانون من اعراض متقدمة لسرطان البروستات وذلك عند عدم توفر أي خيارات أخرى للعلاج، بسبب أعراضة الجانبية الفورية والقوية. وهو ينتمي إلى أسرة من العلاجات تسمى gonadotropin-releasing hormone (GnRH) antagonists.opin-releasing hormone (GnRH) antagonists.
|
| http://dbpedia.org/ontology/alternativeName
|
Plenaxis
|
| http://dbpedia.org/ontology/casNumber
|
183552-38-7
|
| http://dbpedia.org/ontology/chEBI
|
337298
|
| http://dbpedia.org/ontology/chEMBL
|
1252
|
| http://dbpedia.org/ontology/class
|
http://dbpedia.org/resource/Antigonadotropin +
, http://dbpedia.org/resource/GnRH_antagonist +
, http://dbpedia.org/resource/GnRH_analogue +
|
| http://dbpedia.org/ontology/drugbank
|
DB00106
|
| http://dbpedia.org/ontology/fdaUniiCode
|
W486SJ5824
|
| http://dbpedia.org/ontology/kegg
|
D02738
|
| http://dbpedia.org/ontology/pubchem
|
16131215
|
| http://dbpedia.org/ontology/thumbnail
|
http://commons.wikimedia.org/wiki/Special:FilePath/Abarelix.svg?width=300 +
|
| http://dbpedia.org/ontology/wikiPageID
|
1300790
|
| http://dbpedia.org/ontology/wikiPageLength
|
4801
|
| http://dbpedia.org/ontology/wikiPageRevisionID
|
1057371331
|
| http://dbpedia.org/ontology/wikiPageWikiLink
|
http://dbpedia.org/resource/GnRH_antagonist +
, http://dbpedia.org/resource/Testosterone +
, http://dbpedia.org/resource/Gonadotropin-releasing_hormone_antagonist +
, http://dbpedia.org/resource/Gonadotropin-releasing_hormone +
, http://dbpedia.org/resource/United_States +
, http://dbpedia.org/resource/Allergic_reaction +
, http://dbpedia.org/resource/Intramuscular_injection +
, http://dbpedia.org/resource/Germany +
, http://dbpedia.org/resource/Prostate_cancer +
, http://dbpedia.org/resource/Oncology +
, http://dbpedia.org/resource/Gonadotropin-releasing_hormone_receptor +
, http://dbpedia.org/resource/GnRH_analogue +
, http://dbpedia.org/resource/Category:Peptides +
, http://dbpedia.org/resource/Netherlands +
, http://dbpedia.org/resource/Category:GnRH_antagonists +
, http://dbpedia.org/resource/Antigonadotropin +
|
| http://dbpedia.org/property/atcPrefix
|
L02
|
| http://dbpedia.org/property/atcSuffix
|
BX01
|
| http://dbpedia.org/property/c
|
72
|
| http://dbpedia.org/property/casNumber
|
183552
|
| http://dbpedia.org/property/chebi
|
337298
|
| http://dbpedia.org/property/chembl
|
1252
|
| http://dbpedia.org/property/chemspiderid
|
10482301
|
| http://dbpedia.org/property/cl
|
1
|
| http://dbpedia.org/property/class
|
http://dbpedia.org/resource/Antigonadotropin +
, http://dbpedia.org/resource/GnRH_antagonist +
, http://dbpedia.org/resource/GnRH_analogue +
|
| http://dbpedia.org/property/drugbank
|
DB00106
|
| http://dbpedia.org/property/h
|
95
|
| http://dbpedia.org/property/iupacName
|
N-acetyl-3--D-alanyl-4-chloro-D-phenylalanyl-3--D-alanyl-L-seryl-N-methyl-L-tyrosyl-D-asparagyl-L-leucyl-N6-isopropyl-L-lysyl-L-prolyl-D-alaninamide
|
| http://dbpedia.org/property/iupharLigand
|
1188
|
| http://dbpedia.org/property/kegg
|
D02738
|
| http://dbpedia.org/property/n
|
14
|
| http://dbpedia.org/property/o
|
14
|
| http://dbpedia.org/property/pregnancyUs
|
X
|
| http://dbpedia.org/property/proteinBound
|
96
|
| http://dbpedia.org/property/pubchem
|
16131215
|
| http://dbpedia.org/property/routesOfAdministration
|
http://dbpedia.org/resource/Intramuscular_injection +
|
| http://dbpedia.org/property/smiles
|
CCC[C@H]CN[C@@H]CN6CCC[C@H]6CN[C@H]C=O
|
| http://dbpedia.org/property/stdinchi
|
1
|
| http://dbpedia.org/property/stdinchikey
|
AIWRTTMUVOZGPW-HSPKUQOVSA-N
|
| http://dbpedia.org/property/tradename
|
Plenaxis
|
| http://dbpedia.org/property/unii
|
W486SJ5824
|
| http://dbpedia.org/property/verifiedfields
|
changed
|
| http://dbpedia.org/property/verifiedrevid
|
477237014
|
| http://dbpedia.org/property/width
|
250
|
| http://dbpedia.org/property/wikiPageUsesTemplate
|
http://dbpedia.org/resource/Template:Reflist +
, http://dbpedia.org/resource/Template:Ebicite +
, http://dbpedia.org/resource/Template:GnRH_and_gonadotropin_receptor_modulators +
, http://dbpedia.org/resource/Template:Cascite +
, http://dbpedia.org/resource/Template:Chemspidercite +
, http://dbpedia.org/resource/Template:Drugbankcite +
, http://dbpedia.org/resource/Template:GnRH_and_gonadotropins +
, http://dbpedia.org/resource/Template:Drugs.com +
, http://dbpedia.org/resource/Template:Stdinchicite +
, http://dbpedia.org/resource/Template:Fdacite +
, http://dbpedia.org/resource/Template:Drugbox +
, http://dbpedia.org/resource/Template:Keggcite +
|
| http://purl.org/dc/terms/subject
|
http://dbpedia.org/resource/Category:Peptides +
, http://dbpedia.org/resource/Category:GnRH_antagonists +
|
| http://purl.org/linguistics/gold/hypernym
|
http://dbpedia.org/resource/Antagonist +
|
| http://www.w3.org/ns/prov#wasDerivedFrom
|
http://en.wikipedia.org/wiki/Abarelix?oldid=1057371331&ns=0 +
|
| http://xmlns.com/foaf/0.1/depiction
|
http://commons.wikimedia.org/wiki/Special:FilePath/Abarelix.svg +
|
| http://xmlns.com/foaf/0.1/isPrimaryTopicOf
|
http://en.wikipedia.org/wiki/Abarelix +
|
| owl:sameAs |
http://ar.dbpedia.org/resource/%D8%A3%D8%A8%D8%A7%D8%B1%D9%8A%D9%84%D9%8A%D9%83%D8%B3_%28%D8%B9%D9%82%D8%A7%D8%B1%29 +
, http://de.dbpedia.org/resource/Abarelix +
, http://sh.dbpedia.org/resource/Abareliks +
, http://rdf.freebase.com/ns/m.04r3kr +
, http://pt.dbpedia.org/resource/Abarelix +
, http://ca.dbpedia.org/resource/Abarelix +
, http://azb.dbpedia.org/resource/%D8%A7%D8%A8%D8%A7%D8%B1%D9%8A%D9%84%D9%8A%D9%83%D8%B3 +
, http://dbpedia.org/resource/Abarelix +
, https://global.dbpedia.org/id/2pzaW +
, http://yago-knowledge.org/resource/Abarelix +
, http://www.wikidata.org/entity/Q305555 +
, http://sr.dbpedia.org/resource/Abareliks +
, http://vi.dbpedia.org/resource/Abarelix +
, http://it.dbpedia.org/resource/Abarelix +
, http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00106 +
|
| rdf:type |
http://dbpedia.org/class/yago/Work100575741 +
, http://dbpedia.org/class/yago/WikicatCancerTreatments +
, http://dbpedia.org/class/yago/Treatment100658082 +
, http://dbpedia.org/class/yago/Care100654885 +
, http://dbpedia.org/class/yago/Event100029378 +
, http://dbpedia.org/class/yago/Part113809207 +
, http://dbpedia.org/class/yago/Relation100031921 +
, http://umbel.org/umbel/rc/DrugProduct +
, http://dbpedia.org/class/yago/Act100030358 +
, http://dbpedia.org/class/yago/WikicatPeptides +
, http://dbpedia.org/class/yago/PhysicalEntity100001930 +
, http://www.wikidata.org/entity/Q8386 +
, http://dbpedia.org/class/yago/Abstraction100002137 +
, http://dbpedia.org/ontology/Drug +
, http://dbpedia.org/class/yago/YagoPermanentlyLocatedEntity +
, http://dbpedia.org/class/yago/Matter100020827 +
, http://dbpedia.org/class/yago/Protein114728724 +
, http://dbpedia.org/class/yago/OrganicCompound114727670 +
, http://dbpedia.org/class/yago/PsychologicalFeature100023100 +
, http://dbpedia.org/class/yago/Material114580897 +
, http://dbpedia.org/class/yago/Macromolecule114944888 +
, http://dbpedia.org/class/yago/Molecule114682133 +
, http://dbpedia.org/class/yago/Unit109465459 +
, http://dbpedia.org/class/yago/Compound114818238 +
, http://dbpedia.org/class/yago/Chemical114806838 +
, http://dbpedia.org/class/yago/Substance100019613 +
, http://dbpedia.org/class/yago/Thing100002452 +
, http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#ChemicalObject +
, http://dbpedia.org/ontology/ChemicalSubstance +
, http://dbpedia.org/class/yago/Activity100407535 +
, http://dbpedia.org/class/yago/Amide114724264 +
, http://dbpedia.org/class/yago/Peptide114743046 +
|
| rdfs:comment |
Abarelix (Handelsname: Plenaxis®) ist ein Arzneistoff aus der Gruppe der GnRH-Antagonisten, der zur Behandlung des fortgeschrittenen oder metastasierten hormonabhängigen Prostatakarzinoms eingesetzt wird.
, Abarelix é um fármaco antagonista da GnRH. É utilizado principalmente na oncologia para reduzir a quantidade de testosterona dos pacientes com câncer de próstata avançado que não obtiveram sucesso com outros tratamentos.
, أباريليكس (بالإنجليزية: Abarelix) كما يدع … أباريليكس (بالإنجليزية: Abarelix) كما يدعى plenaxis. دواء يستخدم لخفض كمية التيستوستيرون المنتج في أجسام المرضى الذين يعانون من اعراض متقدمة لسرطان البروستات وذلك عند عدم توفر أي خيارات أخرى للعلاج، بسبب أعراضة الجانبية الفورية والقوية. وهو ينتمي إلى أسرة من العلاجات تسمى gonadotropin-releasing hormone (GnRH) antagonists.opin-releasing hormone (GnRH) antagonists.
, Abarelix, sold under the brand name Plenax … Abarelix, sold under the brand name Plenaxis, is an injectable gonadotropin-releasing hormone antagonist (GnRH antagonist) which is marketed in Germany and the Netherlands. It is primarily used in oncology to reduce the amount of testosterone made in patients with advanced symptomatic prostate cancer for which no other treatment options are available. no other treatment options are available.
, Abarelix, venut amb la marca Plenaxis, és … Abarelix, venut amb la marca Plenaxis, és un antagonista injectable de l'hormona alliberadora de gonadotropines (antagonista de la GnRH) que es comercialitza a Alemanya i els Països Baixos. S'utilitza principalment en oncologia per reduir la quantitat de testosterona produïda en pacients amb càncer de pròstata simptomàtic avançat per al qual no hi ha altres opcions de tractament disponibles. altres opcions de tractament disponibles.
, L'abarelix è un antagonista dell'ormone di … L'abarelix è un antagonista dell'ormone di rilascio delle gonadotropine, l'ormone di rilascio delle gonadotropine. È utilizzato principalmente in oncologia per ridurre la quantità di testosterone in pazienti con tumore avanzato della prostata sintomatico per i quali non sono disponibili altre opzioni di trattamento. È commercializzato da Speciality European Pharma come Plenaxis. Plenaxis ha ricevuto l'autorizzazione all'immissione in commercio in Germania.e all'immissione in commercio in Germania.
|
| rdfs:label |
Abarelix
, أباريليكس (عقار)
|
